Core Insights - Can-Fite BioPharma Ltd. announced that Piclidenoson demonstrated efficacy in an experimental model of vascular dementia, as shown by a study from UCLA [1][2] Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing small molecule drugs for cancer and inflammatory diseases [1][6] - The company's lead drug candidate, Piclidenoson, has shown a compelling safety profile in clinical studies and is currently in pivotal Phase 3 trials for psoriasis [5][6] Vascular Dementia Market - Vascular dementia is the second most common cause of dementia, with no FDA-approved therapies available, leading to a significant unmet medical need [3][4] - The global market for vascular dementia is estimated at $6 billion in 2025, with a projected CAGR of 5% through 2035 [3] Drug Mechanism and Potential - Piclidenoson is a selective A3 adenosine receptor agonist that has shown neuroprotective effects and the potential to improve vascular health, addressing a significant gap in the current treatment landscape for vascular dementia [4][5]